Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Eli Lilly has been unable to secure ... and it remains to be seen if either drug will hit the mark in phase 3. Lilly's head of neuroscience R&D Anne White said the company is confident that ...

Uncertainty around President Donald Trump’s tariff policies have sent the major averages on a roller-coaster ride and spurred ...

New investors in the round included Nextech Invest, T Rowe Price Associates, Janus Henderson Investors, RA Capital Management, OrbiMed, Surveyor Capital, Medicxi, Logos Capital, Octagon Capital ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

March 12 (Reuters) - U.S. drugmakers Johnson & Johnson (JNJ.N), opens new tab and Eli Lilly (LLY.N), opens new tab increased spending on security for their top executives in 2024, citing increased ...